The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy

Antiviral Research

Volumn 96, Issue 3, 2012, Pages 405-413

  Chang, Jinhong ^a   Block, Timothy M ^a   Guo, Ju Tao ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis B virus; Interferons; Pattern recognition receptors; TLR7 agonists; Toll like receptors

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALPHA INTERFERON; ANTIVIRUS AGENT; DOUBLE STRANDED DNA; GAMMA INTERFERON; GS 9620; IMIQUIMOD; KIN 101; PATTERN RECOGNITION RECEPTOR; PEGINTERFERON ALPHA; PEGINTERFERON LAMBDA; POLYINOSINIC POLYCYTIDYLIC ACID; POLYRIBOCYTIDIC POLYRIBOSINIC ACID; RIBAVIRIN; RIG I LIKE RECEPTOR AGONIST; RINTATOLIMOD; RO 907501; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGONIST; ANEMIA; ANTIVIRAL THERAPY; ANXIETY; BONE MARROW SUPPRESSION; CYTOKINE RELEASE; DEPRESSION; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; INNATE IMMUNITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VERRUCA VULGARIS; VIRUS CELL INTERACTION; VIRUS LOAD; VIRUS NUCLEOCAPSID; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; INTERFERONS; NUCLEOCAPSID PROTEINS; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84869118771     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.10.001     Document Type: Review

References (113)

1. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413(6857):732-738.
2. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006, 80(9):4501-4509.
3. Bartlett N.W., Buttigieg K., Kotenko S.V., Smith G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 2005, 86(Pt 6):1589-1596.
4. Baumert T.F., Rosler C., Malim M.H., von Weizsacker F. Hepatitis B virus DNA is subject to extensive editing by the human deaminase APOBEC3C. Hepatology 2007, 46(3):682-689.
5. Bedard K.M., Wang M.L., Proll S.C., Loo Y.M., Katze M.G., Gale M., Iadonato S.P. Isoflavone agonists of IRF-3 dependent signaling have antiviral activity against RNA viruses. J. Virol. 2012, 86(13):7334-7344.
6. Belloni L., Allweiss L., Guerrieri F., Pediconi N., Volz T., Pollicino T., Petersen J., Raimondo G., Dandri M., Levrero M. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J. Clin. Invest. 2012, 122(2):529-537.
7. Bertoletti A., Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2011.
8. Bertoletti A., Maini M.K., Ferrari C. The host-pathogen interaction during HBV infection: immunological controversies. Antivir. Ther. 2010, 15(Suppl 3):15-24.
9. Biermer M., Puro R., Schneider R.J. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid integrity through activation of NF-kappaB. J. Virol. 2003, 77(7):4033-4042.
10. Buster E.H., Flink H.J., Cakaloglu Y., Simon K., Trojan J., Tabak F., So T.M., Feinman S.V., Mach T., Akarca U.S., Schutten M., Tielemans W., van Vuuren A.J., Hansen B.E., Janssen H.L. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135(2):459-467.
11. Carter W.A., Pitha P.M., Marshall L.W., Tazawa I., Tazawa S., Ts'o P.O. Structural requirements of the rI n-rC n complex for induction of human interferon. J. Mol. Biol. 1972, 70(3):567-587.
12. Cassano N., Mastrandrea V., Principi M., Loconsole F., De Tullio N., Di Leo A., Vena G.A. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J. Biol. Regul. Homeost. Agents 2011, 25(2):285-289.
13. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995, 13:29-60.
14. Christen V., Duong F., Bernsmeier C., Sun D., Nassal M., Heim M.H. Inhibition of alpha interferon signaling by hepatitis B virus. J. Virol. 2007, 81(1):159-165.
15. Christen V., Treves S., Duong F.H., Heim M.H. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatase 2A. Hepatology 2007, 46(2):558-565.
16. Damm J., Wiegand F., Harden L.M., Gerstberger R., Rummel C., Roth J. Fever, sickness behavior, and expression of inflammatory genes in the hypothalamus after systemic and localized subcutaneous stimulation of rats with the toll-like receptor 7 agonist imiquimod. Neuroscience 2012, 201:166-183.
17. Doehle B.P., Chang K., Rustagi A., McNevin J., McElrath M.J., Gale M. Vpu mediates IRF3 depletion during HIV infection by a lysosomal-dependent mechanism. J. Virol. 2012.
18. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 2010, 30(8):555-564.
19. Dunn C., Peppa D., Khanna P., Nebbia G., Jones M., Brendish N., Lascar R.M., Brown D., Gilson R.J., Tedder R.J., Dusheiko G.M., Jacobs M., Klenerman P., Maini M.K. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009, 137(4):1289-1300.
20. Ebert G., Poeck H., Lucifora J., Baschuk N., Esser K., Esposito I., Hartmann G., Protzer U. 5' Triphosphorylated small interfering RNAs control replication of hepatitis B virus and induce an interferon response in human liver cells and mice. Gastroenterology 2011, 141(2):696-706 e1-3.
21. Elco C.P., Guenther J.M., Williams B.R., Sen G.C. Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-κB, and interferon but not toll-like receptor 3. J. Virol. 2005, 79(7):3920-3929.
22. Ermolaeva M.A., Michallet M.C., Papadopoulou N., Utermohlen O., Kranidioti K., Kollias G., Tschopp J., Pasparakis M. Function of TRADD in tumor necrosis factor receptor 1 signaling and in TRIF-dependent inflammatory responses. Nat. Immunol. 2008, 9(9):1037-1046.
23. Fidock M.D., Souberbielle B.E., Laxton C., Rawal J., Delpuech-Adams O., Corey T.P., Colman P., Kumar V., Cheng J.B., Wright K., Srinivasan S., Rana K., Craig C., Horscroft N., Perros M., Westby M., Webster R., van der Ryst E. The innate immune response, clinical outcomes, and Ex Vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin. Pharmacol. Ther. 2011, 89(6):821-829.
24. Field A.K., Lampson G.P., Tytell A.A., Nemes M.M., Hilleman M.R. Inducers of interferon and host resistance, IV. Double-stranded replicative form RNA (MS2-Ff-RNA) from E. coli infected with MS2 coliphage. Proc. Natl. Acad. Sci. U.S.A 1967, 58(5):2102-2108.
25. Fisicaro P., Valdatta C., Boni C., Massari M., Mori C., Zerbini A., Orlandini A., Sacchelli L., Missale G., Ferrari C. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58(7):974-982.
26. Geiss G., Jin G., Guo J., Bumgarner R., Katze M.G., Sen G.C. A comprehensive view of regulation of gene expression by double-stranded RNA-mediated cell signaling. J. Biol. Chem. 2001, 276(32):30178-30182.
27. Guidotti L.G., Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 2006, 1:23-61.
28. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., Chisari F.V. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. U.S.A 1994, 91:3764-3768.
29. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4(1):25-36.
30. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection [In Process Citation]. Science 1999, 284(5415):825-829.
31. Guidotti L.G., Morris A., Mendez H., Koch R., Silverman R.H., Williams B.R., Chisari F.V. Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice. J. Virol. 2002, 76(6):2617-2621.
32. Guo J.-T., Zhou H., Liu C., Aldrich C., Saputelli J., Whitaker T., Barrasa M.I., Mason W.S., Seeger C. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infection. J. Virol. 2000, 74:1495-1505.
33. Guo J.T., Pryce M., Wang X., Barrasa M.I., Hu J., Seeger C. Conditional replication of duck hepatitis B virus in hepatoma cells. J. Virol. 2003, 77(3):1885-1893.
34. Guo H., Jiang D., Ma D., Chang J., Dougherty A.M., Cuconati A., Block T.M., Guo J.T. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. J. Virol. 2009, 83(2):847-858.
35. Guo F., Meads J., Aliya N., Wang L., Cuconati A., Wei L., Li K., Block T.M., Guo J.-T., Chang J. RO 90-7501 enhances TLR3 and RLR agonists induced antiviral response. PLoS ONE 2012, 7(10):e42583.
36. Han Q., Zhang C., Zhang J., Tian Z. Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner. Hepatology 2011, 54(4):1179-1189.
37. Horsmans Y., Berg T., Desager J.P., Mueller T., Schott E., Fletcher S.P., Steffy K.R., Bauman L.A., Kerr B.M., Averett D.R. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology 2005, 42(3):724-731.
38. Hosel M., Quasdorff M., Wiegmann K., Webb D., Zedler U., Broxtermann M., Tedjokusumo R., Esser K., Arzberger S., Kirschning C.J., Langenkamp A., Falk C., Buning H., Rose-John S., Protzer U. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009, 50(6):1773-1782.
39. Ijichi K., Mitamura K., Ida S., Machida H., Shimada K. In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus. J. Med. Virol. 1994, 43(2):161-165.
40. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 2005, 79(11):7269-7272.
41. Jiang D., Guo H., Xu C., Chang J., Gu B., Wang L., Block T.M., Guo J.T. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J. Virol. 2008, 82(4):1665-1678.
42. Jilbert A.R., Wu T.T., England J.M., Hall P.M., Carp N.Z., O'Connell A.P., Mason W.S. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 1992, 66(3):1377-1388.
43. Jost S., Turelli P., Mangeat B., Protzer U., Trono D. Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons. J. Virol. 2007, 81(19):10588-10596.
44. Kajino K., Jilbert A.R., Saputelli J., Aldrich C.E., Cullen J., Mason W.S. Woodchuck hepatitis virus infections: very rapid recovery after a prolonged viremia and infection of virtually every hepatocyte. J. Virol. 1994, 68(9):5792-5803.
45. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat. Med. 2007, 13(5):552-559.
46. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 2008, 205(7):1601-1610.
47. Katze M.G., Fornek J.L., Palermo R.E., Walters K.A., Korth M.J. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat. Rev. Immunol. 2008, 8(8):644-654.
48. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 2010, 11(5):373-384.
49. Kelly C., Klenerman P., Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011, 60(9):1284-1293.
50. Kumar M., Jung S.Y., Hodgson A.J., Madden C.R., Qin J., Slagle B.L. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J. Virol. 2011, 85(2):987-995.
51. Lampertico P., Galmozzi E., Colombo M. Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype. Hepatology 2012.
52. Lanford R.E., Guerra B., Chavez D.C., Hodara V.L., Zheng X., Wolfgang G., Tumas D. Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infectionin chimpanzees. J. Hepatol. 2011, 54:S45. Abstract.
53. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., Gane E., Fried M.W., Chow W.C., Paik S.W., Chang W.Y., Berg T., Flisiak R., McCloud P., Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005, 352(26):2682-2695.
54. Lee W.M. Hepatitis B virus infection. N. Engl. J. Med. 1997, 337(24):1733-1745.
55. Levy H.B., Baer G., Baron S., Buckler C.E., Gibbs C.J., Iadarola M.J., London W.T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 1975, 132(4):434-439.
56. Liu C.J., Lai M.Y., Chao Y.C., Liao L.Y., Yang S.S., Hsiao T.J., Hsieh T.Y., Lin C.L., Hu J.T., Chen C.L., Chen P.J., Kao J.H., Chen D.S. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006, 43(4):742-749.
57. Lok A.S. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S303-S309.
58. Lucifora J., Durantel D., Testoni B., Hantz O., Levrero M., Zoulim F. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010, 51(1):63-72.
59. Lutgehetmann M., Bornscheuer T., Volz T., Allweiss L., Bockmann J.H., Pollok J.M., Lohse A.W., Petersen J., Dandri M. Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice. Gastroenterology 2011, 140(7):2074-2083 e1-2.
60. Makela S.M., Strengell M., Pietila T.E., Osterlund P., Julkunen I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J. Leukoc. Biol. 2009, 85(4):664-672.
61. Mao R., Zhang J., Jiang D., Cai D., Levy J.M., Cuconati A., Block T.M., Guo J.T., Guo H. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells. J. Virol. 2011, 85(2):1048-1057.
62. Marcellin P., Bonino F., Lau G.K., Farci P., Yurdaydin C., Piratvisuth T., Jin R., Gurel S., Lu Z.M., Wu J., Popescu M., Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136(7):2169-2179 e1-4.
63. Marcello T., Grakoui A., Barba-Spaeth G., Machlin E.S., Kotenko S.V., MacDonald M.R., Rice C.M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131(6):1887-1898.
64. McMahon B.J. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 2005, 25(Suppl 1):3-8.
65. Menne S., Tennant B.C., Liu K.H., Ascenzi M.A., Baldwin B.H., Bellezza C.A., Cote P.J., Zheng X., Wolfgang G., Tumas D. Antiviral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J. Hepatol. 2011, 54:S441. Abstract.
66. Mitchell D., Olive C. Regulation of toll-like receptor-induced chemokine production in murine dendritic cells by mitogen-activated protein kinases. Mol. Immunol. 2010, 47(11-12):2065-2073.
67. Muir A.J., Shiffman M.L., Zaman A., Yoffe B., de la Torre A., Flamm S., Gordon S.C., Marotta P., Vierling J.M., Lopez-Talavera J.C., Byrnes-Blake K., Fontana D., Freeman J., Gray T., Hausman D., Hunder N.N., Lawitz E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, 52(3):822-832.
68. Nguyen D.H., Hu J. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 2008, 82(14):6852-6861.
69. Nguyen D.H., Gummuluru S., Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J. Virol. 2007, 81(9):4465-4472.
70. Nicodemus C.F., Berek J.S. TLR3 agonists as immunotherapeutic agents. Immunotherapy 2010, 2(2):137-140.
71. Niu J., Wang Y., Dixon R., Bowden S., Qiao M., Einck L., Locarnini S. The use of ampligen alone and in combination with ganciclovir and coumermycin A1 for the treatment of ducks congenitally-infected with duck hepatitis B virus. Antivir. Res. 1993, 21(2):155-171.
72. O'Neill L.A., Bowie A.G. Sensing and signaling in antiviral innate immunity. Curr. Biol. 2010, 20(7):R328-R333.
73. Onoguchi K., Yoneyama M., Takemura A., Akira S., Taniguchi T., Namiki H., Fujita T. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 2007, 282(10):7576-7581.
74. Osterlund P.I., Pietila T.E., Veckman V., Kotenko S.V., Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 2007, 179(6):3434-3442.
75. Pagliaccetti N.E., Chu E.N., Bolen C.R., Kleinstein S.H., Robek M.D. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010, 401(2):197-206.
76. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009, 49(5 Suppl):S103-S111.
77. Pockros P.J., Jeffers L., Afdhal N., Goodman Z.D., Nelson D., Gish R.G., Reddy K.R., Reindollar R., Rodriguez-Torres M., Sullivan S., Blatt L.M., Faris-Young S. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 2007, 45(3):569-578.
78. Purcell R.H., London W.T., McAuliffe V.J., Palmer A.E., Kaplan P.M., Gerin J.L., Wagner J., Popper H., Lvovsky E., Wong D.C., Levy H.B. Modification of chronic hepatitis-B virus infection in chimpanzees by administration of an interferon inducer. Lancet 1976, 2(7989):757-761.
79. Puro R., Schneider R.J. Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J. Virol. 2007, 81(14):7351-7362.
80. Rijckborst V., ter Borg M.J., Cakaloglu Y., Ferenci P., Tabak F., Akdogan M., Simon K., Raptopoulou-Gigi M., Ormeci N., Zondervan P.E., Verhey E., van Vuuren A.J., Hansen B.E., Janssen H.L. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am. J. Gastroenterol. 2010, 105(8):1762-1769.
81. Robek M.D., Wieland S.F., Chisari F.V. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J. Virol. 2002, 76(7):3570-3574.
82. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 2005, 79(6):3851-3854.
83. Robek M.D., Garcia M.L., Boyd B.S., Chisari F.V. Role of immunoproteasome catalytic subunits in the immune response to hepatitis B virus. J. Virol. 2007, 81(2):483-491.
84. Rosler C., Kock J., Kann M., Malim M.H., Blum H.E., Baumert T.F., von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005, 42(2):301-309.
85. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008, 8(7):559-568.
86. Schrofelbauer B., Raffetseder J., Hauner M., Wolkerstorfer A., Ernst W., Szolar O.H. Glycyrrhizin, the main active compound in liquorice, attenuates pro-inflammatory responses by interfering with membrane-dependent receptor signalling. Biochem. J. 2009, 421(3):473-482.
87. Schultz U., Summers J., Staeheli P., Chisari F.V. Elimination of duck hepatitis B virus RNA-containing capsids in duck interferon-alpha-treated hepatocytes. J. Virol. 1999, 73(7):5459-5465.
88. Sonneveld M.J., Wong V.W., Woltman A.M., Wong G.L., Cakaloglu Y., Zeuzem S., Buster E.H., Uitterlinden A.G., Hansen B.E., Chan H.L., Janssen H.L. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012, 142(3):513-520 e1.
89. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 1998, 67:227-264.
90. Steer S.A., Moran J.M., Christmann B.S., Maggi L.B., Corbett J.A. Role of MAPK in the regulation of double-stranded RNA- and encephalomyocarditis virus-induced cyclooxygenase-2 expression by macrophages. J. Immunol. 2006, 177(5):3413-3420.
91. Stewart M.J., Kulkarni S.B., Meusel T.R., Imani F. C-Jun N-terminal kinase negatively regulates dsRNA and RSV induction of tumor necrosis factor-alpha transcription in human epithelial cells. J. Interferon Cytokine Res. 2006, 26(8):521-533.
92. Su A.I., Pezacki J.P., Wodicka L., Brideau A.D., Supekova L., Thimme R., Wieland S., Bukh J., Purcell R.H., Schultz P.G., Chisari F.V. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A 2002, 99(24):15669-15674.
93. Summers J., Jilbert A.R., Yang W., Aldrich C.E., Saputelli J., Litwin S., Toll E., Mason W.S. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc. Natl. Acad. Sci. U.S.A 2003, 100(20):11652-11659.
94. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140(6):805-820.
95. Vartanian J.P., Henry M., Marchio A., Suspene R., Aynaud M.M., Guetard D., Cervantes-Gonzalez M., Battiston C., Mazzaferro V., Pineau P., Dejean A., Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 2010, 6(5):e1000928.
96. Vincent I.E., Zannetti C., Lucifora J., Norder H., Protzer U., Hainaut P., Zoulim F., Tommasino M., Trepo C., Hasan U., Chemin I. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS ONE 2011, 6(10):e26315.
97. Visvanathan K., Skinner N.A., Thompson A.J., Riordan S.M., Sozzi V., Edwards R., Rodgers S., Kurtovic J., Chang J., Lewin S., Desmond P., Locarnini S. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology 2007, 45(1):102-110.
98. Volz T., Lutgehetmann M., Allweiss L., Bornscheuer T., Lohse A.W., Ma H., Klumpp K., Peterssen J., Lopatin U., Fletcher S., Dandri M. Spreading of hepatitis B virus infection in uPA mice is sensed by innate antiviral defense mechanisms of human hepatocytes. J. Hepatol. 2011, 54:S447. Abstract.
99. Wang H., Ryu W.S. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. PLoS Pathog. 2010, 6(7):e1000986.
100. Wang H.C., Wu H.C., Chen C.F., Fausto N., Lei H.Y., Su I.J. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am. J. Pathol. 2003, 163(6):2441-2449.
101. Wang Z., Ni J., Li J., Shi B., Xu Y., Yuan Z. Inhibition of hepatitis B virus replication by cIAP2 involves accelerating the ubiquitin-proteasome-mediated destruction of polymerase. J. Virol. 2011, 85(21):11457-11467.
102. Wang N., Dong Q., Li J., Jangra R.K., Fan M., Brasier A.R., Lemon S.M., Pfeffer L.M., Li K. Viral induction of the zinc finger antiviral protein is IRF3-dependent but NF-κB-independent. J. Biol. Chem. 2010, 285(9):6080-6090.
103. Watts C., West M.A., Zaru R. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol. 2010, 22(1):124-130.
104. Wei C., Ni C., Song T., Liu Y., Yang X., Zheng Z., Jia Y., Yuan Y., Guan K., Xu Y., Cheng X., Zhang Y., Wang Y., Wen C., Wu Q., Shi W., Zhong H. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. J. Immunol. 2010, 185(2):1158-1168.
105. Wieland S., Thimme R., Purcell R.H., Chisari F.V. Genomic analysis of the host response to hepatitis B virus infection. Proc. Natl. Acad. Sci. U.S.A 2004, 101(17):6669-6674.
106. Wieland S.F., Eustaquio A., Whitten-Bauer C., Boyd B., Chisari F.V. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc. Natl. Acad. Sci. U.S.A 2005, 102(28):9913-9917.
107. Woltman A.M., Op den Brouw M.L., Biesta P.J., Shi C.C., Janssen H.L. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS ONE 2011, 6(1):e15324.
108. Wu J., Lu M., Meng Z., Trippler M., Broering R., Szczeponek A., Krux F., Dittmer U., Roggendorf M., Gerken G., Schlaak J.F. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007, 46(6):1769-1778.
109. Wu J., Meng Z., Jiang M., Pei R., Trippler M., Broering R., Bucchi A., Sowa J.P., Dittmer U., Yang D., Roggendorf M., Gerken G., Lu M., Schlaak J.F. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009, 49(4):1132-1140.
110. Xu C., Guo H., Pan X.B., Mao R., Yu W., Xu X., Wei L., Chang J., Block T.M., Guo J.T. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J. Virol. 2010, 84(18):9332-9340.
111. Yu S., Chen J., Wu M., Chen H., Kato N., Yuan Z. Hepatitis B virus polymerase inhibits RIG-I- and toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. J. Gen. Virol. 2010, 91(Pt 8):2080-2090.
112. Zeissig S., Murata K., Sweet L., Publicover J., Hu Z., Kaser A., Bosse E., Iqbal J., Hussain M.M., Balschun K., Rocken C., Arlt A., Gunther R., Hampe J., Schreiber S., Baron J.L., Moody D.B., Liang T.J., Blumberg R.S. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nat. Med. 2012.
113. Zhang Z., Zhang S., Zou Z., Shi J., Zhao J., Fan R., Qin E., Li B., Li Z., Xu X., Fu J., Zhang J., Gao B., Tian Z., Wang F.S. Hypercytolytic activity of hepatic natural killer cells correlates with liver injury in chronic hepatitis B patients. Hepatology 2011, 53(1):73-85.